Profile data is unavailable for this security.
About the company
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
- Revenue in USD (TTM)0.00
- Net income in USD-15.31m
- Incorporated2021
- Employees6.00
- LocationAllarity Therapeutics Inc24 School St., 2Nd FloorBOSTON 02108United StatesUSA
- Phone+1 (401) 426-4664
- Fax+1 (302) 655-5049
- Websitehttps://allarity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioCardia Inc | 0.00 | -8.54m | 14.33m | 17.00 | -- | 5.45 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 14.47m | 11.00 | -- | 1.79 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Curis Inc | 11.65m | -36.56m | 14.83m | 33.00 | -- | -- | -- | 1.27 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 15.05m | 9.00 | -- | -- | -- | 38.59 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Bioatla Inc | 0.00 | -64.71m | 15.15m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -36.89m | 15.42m | 20.00 | -- | 0.4436 | -- | -- | -7,083.74 | -7,083.74 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.56m | 360.00 | -- | -- | -- | 0.0108 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 16.00m | 6.00 | -- | 1.33 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Citius Pharmaceuticals Inc | 3.94m | -35.89m | 16.18m | 23.00 | -- | 0.2023 | -- | 4.10 | -2.92 | -2.92 | 0.2707 | 3.57 | 0.0302 | 0.0426 | -- | 171,483.00 | -29.76 | -29.86 | -48.25 | -35.19 | 79.99 | -- | -985.09 | -- | 0.4006 | -128.99 | 0.0106 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| IN8bio Inc | 0.00 | -20.66m | 16.60m | 18.00 | -- | 0.5915 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Regentis Biomaterials Ltd | 0.00 | -13.65m | 16.68m | -- | -- | 3.52 | -- | -- | -24.08 | -24.08 | 0.00 | 0.9159 | 0.00 | -- | -- | -- | -336.99 | -188.09 | -- | -- | -- | -- | -- | -- | -- | -1.02 | 0.2015 | -- | -- | -- | -360.91 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 16.71m | 2.00 | -- | 7.09 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 16.98m | 2.00 | -- | 2.08 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 17.26m | 3.00 | -- | 5,002.13 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 17.45m | 4.00 | -- | 302.69 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 17.71m | 2.00 | -- | 2.25 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Allarity Therapeutics Inc's reporting currency: US Dollar USD
7.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2025 | 247.61k | 1.54% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 171.80k | 1.07% |
| Geode Capital Management LLCas of 31 Dec 2025 | 156.64k | 0.98% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 137.60k | 0.86% |
| DRW Securities LLCas of 31 Dec 2025 | 122.74k | 0.76% |
| Capital Advisors, Inc. (Oklahoma)as of 31 Dec 2025 | 100.00k | 0.62% |
| Citadel Securities LLCas of 31 Dec 2025 | 84.59k | 0.53% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 74.91k | 0.47% |
| Private Advisor Group LLCas of 31 Dec 2025 | 55.54k | 0.35% |
| XTX Markets LLCas of 31 Dec 2025 | 33.64k | 0.21% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
